To study the clinical efficacy of Ginkgolide Dispersible Tablets combined with hyperbaric oxygen in the treatment of acute cerebral infarction（ACI）.

A total of 326 patients with ACIwho were treated in the hospital from April 2019 to October 2022 were selected as the study subjects.They were divided into treatment group（163 cases）and control group（163 cases）according to different intervention methods.Both groups received symptomatic treatment such as oxygen inhalation，blood pressure reduction and lipid regulation，and anti-platelet aggregation.On this basis，the treatment group was treated with Ginkgolide Dispersible Tablets and hyperbaric oxygen，while the control group was only treated with hyperbaric oxygen，and the patients in both groups were treated continuously for 2 weeks.The levels of carotid atherosclerosis indicators［carotid intimamedia thickness（IMT），carotid plaque area］，NF-κB signaling pathway-related factors（NF-κB p50，p65 mRNA and protein），and downstream inflammatory factors［interleukin-8（IL-8），interleukin-1β（IL-1β），tumor necrosis factor-alpha（TNF-α）］were measured before and after treatment.Simultaneously，Barthel Index（BI）scores，National Institutes of Health Stroke Scale（NIHSS）scores，traditional Chinese medicine syndrome scores were assessed.Additionally，the clinical efficacy was evaluated after the course of treatment and the drug-related adverse events during the trial period were recorded.

After treatment，the total effective rate of the treatment group was 95.71%，higher than that of the control group（84.66%）.There was a significant difference between the two groups（P<0.05），but there was no significant difference in adverse events between the two groups（P>0.05）.At the same time，the BI scores of the two groups were significantly higher after treatment，and BI score of the treatment group was higher than that of the control group（P<0.05）.The NIHSS score，traditional Chinese medicine syndrome points，IMT，plaque area and the levels of TNF-α，IL-8，IL-1β，NF-κB p50，p65 mRNA and protein were significantly lower in the treatment group than those in the control group（P<0.05）.

Ginkgolide Dispersible Tablets combined with hyperbaric oxygen can significantly inhibit the activation of NF-κB inflammatory signal pathway in patients with ACI and improve its inflammatory damage status，further stabilizing the atherosclerotic plaque，significantly improving the clinical efficacy，with less adverse reactions.And at the same time，it is conducive to the optimization of neurological function and quality of prognosis.